Bambusa Therapeutics
Austin, US · Founded 2024 · Delaware corporation · 6 known investors
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.
Founders & leadership
Bambusa Therapeutics was founded in 2024 by Shanshan Xu and Helmut Jeggle.
Investors · 6
Competitors · 3
by search overlapBioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode Therapeutics10 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Agenus9 shared keywords
Companies competing with Bambusa Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$67.4M disclosed across 3 rounds · 2024–2025
▶$53.3MraisedFeb 2025 · 16 investors · BiotechnologyRule 506(b)
▶$53.3MraisedFeb 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean MarettDirector
- Helmut JeggleDirector
- Derek DiRoccoDirector
- Shanshan XuExecutive Officer, Director, Promoter
- Offering amount
- $88.9M
- Amount sold
- $53.3M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$5.1MraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shanshan XuExecutive Officer, Director, Promoter
- Helmut JeggleDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$9MraisedJan 2025 · 9 investors · BiotechnologyRule 506(b)
▶$9MraisedJan 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Helmut JeggleDirector
- Shanshan XuExecutive Officer, Director, Promoter
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Bambusa Therapeutics do?
- Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.
- Who founded Bambusa Therapeutics?
- Bambusa Therapeutics was founded by Shanshan Xu, Helmut Jeggle in 2024.
- Who are Bambusa Therapeutics's investors?
- Bambusa Therapeutics's investors include INCE Capital, RA Capital, Biotechnology Value Fund, Janus Henderson Investors, REDMILE, Salvia.
- How much funding has Bambusa Therapeutics raised?
- Bambusa Therapeutics has disclosed $67.4M raised across 3 rounds.
- Where is Bambusa Therapeutics headquartered?
- Bambusa Therapeutics is headquartered in Austin, US.